[Skip to Content]
[Skip to Content Landing]
Other Articles
June 23, 1962

Treatment of Adrenogenital Syndrome: Intramuscular Therapy with Long-Acting Prednisteroids

Author Affiliations

New Orleans

From the Division of Endocrinology, Department of Medicine, Tulane University School of Medicine, and Tulane Endocrine Clinic, Charity Hospital.; Formerly associate professor of Medicine, Director, Division of Endocrinology, Tulane Medical School and Tulane Endocrine Clinic, Charity Hospital; now Director of Medical Research, The Frank H. Lahey Foundation, and Director, Lahey Foundation Metabolic Research Unit, Robert Breck Brigham Hospital, Boston (Dr. Dingman). Clinical trainees of the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health (Drs. Maranan and Staub). Dr. Maranan's present address is: Department of Medicine, Santos Tomas University School of Medicine, Manila, Philippines.; Dr. Staub's present address is: Department of Medicine, University of Zurich School of Medicine, Zurich, Switzerland.

JAMA. 1962;180(12):1017-1020. doi:10.1001/jama.1962.03050250023005

Ten women and 6 children with adrenogenital syndrome were treated with injections of prednisolone trimethylacetate or methylprednisolone acetate at 2- to 3-week intervals for periods of as long as 22 months. Both steroids produced satisfactory adrenal suppression in most patients, but prednisolone trimethylacetate appeared to be slightly more effective than equivalent doses of methylprednisolone acetate in lowering urinary 17-ketosteroids and improving menstrual function in the adults. There was, however, no apparent difference in the therapeutic action of either steroid in the children. The advantage of intermittent parenteral therapy over daily oral therapy in some patients is briefly discussed.